Enzo Biochem v. J&J
This article was originally published in The Gray Sheet
Executive Summary
Litigants enter settlement whereby Johnson & Johnson and subsidiary Ortho agree to pay Enzo $35 mil. "for research and development work conducted by Enzo under [an earlier] agreement and to settle all claims the parties may have had against each other arising out of the agreement," Enzo announces Oct. 20. Enzo had filed the suit in 1987, charging breach of contract of a development agreement relating to Enzo DNA probes. The suit sought $100 mil. in compensatory damages and $500 mil. in punitive damages. Enzo estimates that it spent $2 mil. pursuing the litigation
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.